



Cite this: *RSC Chem. Biol.*, 2021, 2, 486

## Metal transport mechanism of the cation diffusion facilitator (CDF) protein family – a structural perspective on human CDF (ZnT)-related diseases†

Shiran Barber-Zucker, \*<sup>a</sup> Arie Moran<sup>b</sup> and Raz Zarivach \*<sup>a</sup>

Divalent d-block metal cations (DDMCs) participate in many cellular functions; however, their accumulation in cells can be cytotoxic. The cation diffusion facilitator (CDF) family is a ubiquitous family of transmembrane DDMC exporters that ensures their homeostasis. Severe diseases, such as type II diabetes, Parkinson's and Alzheimer's disease, were linked to dysfunctional human CDF proteins, ZnT-1-10 (SLC30A1-10). Each member of the CDF family reduces the cytosolic concentration of a specific DDMC by transporting it from the cytoplasm to the extracellular environment or into intracellular compartments. This process is usually achieved by utilizing the proton motive force. In addition to their activity as DDMC transporters, CDFs also have other cellular functions such as the regulation of ion channels and enzymatic activity. The combination of structural and biophysical studies of different bacterial and eukaryotic CDF proteins led to significant progress in the understanding of the mutual interaction among CDFs and DDMCs, their involvement in ion binding and selectivity, conformational changes and the consequent transporting mechanisms. Here, we review these studies, provide our mechanistic interpretation of CDF proteins based on the current literature and relate the above to known human CDF-related diseases. Our analysis provides a common structure–function relationship to this important protein family and closes the gap between eukaryote and prokaryote CDFs.

Received 8th October 2020,  
Accepted 26th December 2020

DOI: 10.1039/d0cb00181c

rsc.li/rsc-chembio

<sup>a</sup> Department of Life Sciences, the National Institute for Biotechnology in the Negev and Ilse Katz Institute for Nanoscale Science and Technology, Ben-Gurion University of the Negev, P.O.B. 653, Beer Sheva, 8410501, Israel. E-mail: barbers@post.bgu.ac.il, shiranbarber@gmail.com, zarivach@bgu.ac.il; Fax: +972-8-6472970, +972-8-6472970; Tel: +972-8-6428447, +972-8-6461999

<sup>b</sup> Department of Physiology and Cell Biology, Faculty of Health Sciences, Ben-Gurion University of the Negev, P.O.B. 653, Beer Sheva, 8410501, Israel

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0cb00181c



**Shiran Barber-Zucker**

*Dr Shiran Barber-Zucker received her PhD in 2019 from the Department of Life Sciences at Ben-Gurion University of the Negev, Beer Sheva, Israel, where she was investigating the structure–function relationship of the cation diffusion facilitator protein family under the guidance of Prof. Raz Zarivach. Shiran is currently a postdoctoral fellow at the Weizmann Institute of Science, Rehovot, Israel, under the guidance of Prof. Sarel Fleishman. She is developing computational methods for the design of highly efficient and selective enzymes for environmental applications.*



**Arie Moran**

*Prof. Moran received his degrees from the physiology department at Hadassah Medical School in the Hebrew University, Jerusalem. His current work utilizes in vitro and in vivo systems to study the role of ZnT-1 in zinc and calcium homeostasis in cardiac cells. He served as the chairman of the Department of Physiology and Vice Dean for Research at the Faculty of Health Sciences and for seven year as the Deputy Vice-President and Dean for Research and Development at Ben-Gurion University of the Negev. Since 2010 he is also a Visiting Professor at the University of Sydney, Sydney, Australia.*



## Introduction

Divalent d-block metal cations (DDMCs), such as  $\text{Mn}^{2+}$ ,  $\text{Zn}^{2+}$  and  $\text{Fe}^{2+}$ , are the key components for cell function. These cations play a role in many biological processes, for example, they serve as protein structural anchors and stabilize the active sites of enzymes. Only a few amino acids bind with DDMCs, which are usually ligated by a combination of cysteine, histidine, glutamate and aspartate. However, DDMCs are bound with various affinities, specific coordination geometry and selectivity to metalloproteins. This allows, in the context of their specific cellular environment, their folding, thermostability and kinetic property optimization.<sup>1–4</sup> The affinities of DDMCs to different ligands follow the Irving–Williams series that ranks the relative stability of their complexes as follows:  $\text{Mn}^{2+} < \text{Fe}^{2+} < \text{Co}^{2+} < \text{Ni}^{2+} < \text{Cu}^{2+} > \text{Zn}^{2+}$ , meaning that  $\text{Zn}^{2+}$  forms more stable complexes than  $\text{Mn}^{2+}$ . This is usually correlated inversely with the cellular concentrations of the DDMCs in the cytosol, thus preventing the replacement of strong binding ions with weaker binding ones.<sup>4,5</sup> Together with import proteins, the exporter cation diffusion facilitator (CDF) protein family is one of the major systems that ensures homeostasis of various DDMCs.

CDF proteins can act as DDMC transporters and usually utilize proton motive force for either extruding DDMCs from the cytoplasm to the extracellular environment or to sequester the DDMCs into cellular components.<sup>6,7</sup> CDFs are conserved throughout evolution (see Fig. S1, ESI<sup>†</sup>), with humans having ten CDF proteins, named ZnT-1-10 (for zinc transporters, named as such after the first member of the family which was defined as a zinc transporter). The members of the family selectively transport either  $\text{Zn}^{2+}$  or  $\text{Mn}^{2+}$ .<sup>8–13</sup> Human ZnTs are highly important for normal cell function, as mutations and amino acid variations within them, and irregularity in their expression or function, were correlated with severe disorders and diseases. Among these are Alzheimer's disease,<sup>14–16</sup> transient neonatal zinc deficiency,<sup>17–20</sup> type II diabetes,<sup>21</sup> and

Parkinsonism.<sup>22,23</sup> Furthermore, recently it became clear that, in addition to their activity as transporters, mammalian CDFs also act as regulators of other cellular functions; for example, ZnT-1, in addition to its activity as a  $\text{Zn}^{2+}/\text{H}^{+}$  exchanger, acts as a modulator of voltage gated calcium channels (VGCCs), inhibiting  $\text{Ca}^{2+}$  influx *via* L-type calcium channels (LTCCs), and acts as an activator of the Ras-Raf-ERK signaling pathway.<sup>12,24–27</sup> Analyses performed on several plant and human CDF proteins showed structural similarities between bacterial, mammalian and plant CDF proteins;<sup>28–34</sup> however, the information we have on eukaryotic CDFs is far from being as comprehensive as that on bacterial proteins,<sup>6</sup> which limits our understanding of human disorders and diseases. Here, we review the present functional, biophysical and structural studies of CDF proteins and provide a mechanistic interpretation. Based on these, we provide a structural perspective on how specific mutations in ZnTs may cause their malfunction, leading to their corresponding diseases.

## The general architecture of CDF proteins

The CDF structure–function knowledge is based on the bacterial CDF protein YiiP<sup>8</sup> and the human CDF protein ZnT-8. Full *Escherichia coli* YiiP (EcYiiP), *Shewanella oneidensis* YiiP homolog (SoYiiP)<sup>35,36</sup> and human ZnT-8 (isoform B) structures were determined<sup>34,37,38</sup> in the presence of  $\text{Zn}^{2+}$  (Fig. 1).

CDF proteins form dimers, made of two monomers including a six-helical transmembrane bundle N-terminal domain (NTD), through which the cations are transported, and a C-terminal domain (CTD). YiiP structures exhibit dimeric fold with similar CTD conformation but different transmembrane domain (TMD) arrangements (open and closed states, see Fig. 1A), and both have three metal binding sites (A–C sites)<sup>35–38</sup> (Fig. 1B). ZnT-8 structures have high similarity to bacterial ones with similar CTD and inward-facing TMD conformations (Fig. 1C) and, similarly to YiiP, have three metal binding sites ( $S_{\text{tm}}$ ,  $S_{\text{if}}$ , and two  $S_{\text{cd}}$  sites, Fig. 1D).<sup>34</sup> The YiiP A-site/ $S_{\text{tm}}$  in ZnT-8, the active transport site within the cation transport path, is found in both monomers and composed of two residues from transmembrane helix (TMH) 2 and two residues from TMH5 (the DD-HD quartet in YiiP and HD-HD in ZnT-8). This site is structurally conserved in all CDFs and contains four metal binding residues (see Fig. S1, ESI<sup>†</sup>). The symmetrical, not conserved, B-site in YiiP is located on an intracellular loop between TMH2 and TMH3 and is predicted to be involved in CDF dimerization.<sup>39</sup> The symmetrical  $S_{\text{if}}$  site in ZnT-8 is found in the interface between the CTD and TMD, in the cytosolic entrance to the  $\text{Zn}^{2+}$  transport pathway, and has been suggested to have a role in increasing the  $\text{Zn}^{2+}$  local concentration to facilitate its transport.<sup>34</sup> The two symmetrical C-sites in YiiP are located at the CTD and contain four structural  $\text{Zn}^{2+}$  cations that are bound by a network of residues from both monomers. The site occupancy is related to the CTD conformation and dimerization.<sup>36,38,40,41</sup> Although the CTD C-site is not conserved in all characterized CTD-containing




**Raz Zarivach**

*Prof. Zarivach received his PhD in 2005 from the Department of Structural Biology at the Weizmann Institute of Science, Rehovot, Israel, under the guidance of Prof. Ada Yonath. Subsequently he was a post-doctoral fellow at the University of British Columbia, Canada with Prof. Natalie Strynadka (2005–2008). Since 2008 he has been a principal investigator in the Department of Life Sciences, Ben-Gurion University of the*

*Negev in the field of structural biology. His research is focused on the structural studies of biological macromolecules including biomineralizing proteins and metal transporters.*





**Fig. 1** Structures and DDMC binding sites of full YiiP and human ZnT-8 (isoform B) proteins. (A) Left: crystal structure of full YiiP from *Escherichia coli* (PDB code: 3H90,<sup>38</sup> light green). Middle: cryo-EM structure of the YiiP homolog from *Shewanella oneidensis* (PDB code: 5VRF,<sup>36</sup> light blue); the  $Zn^{2+}$  ions are presented as yellow spheres, whereas the A-, B- and C-sites are marked in pink. Right: both YiiP structures overlapped onto each other, displaying the different conformations of the TMD and the suggested scissor-like motion. (B) Detailed high magnification of A–C  $Zn^{2+}$  binding sites of YiiP from *Escherichia coli*.  $Zn^{2+}$  ions are presented in yellow and the coordination first-shell residues are presented as sticks. The superscript 2 and the darker green color mark the second monomer. (C) Left: cryo-EM structure of WT human ZnT-8 in the presence of  $Zn^{2+}$  (PDB code: 6XPE,<sup>34</sup> coral). Middle: low-resolution cryo-EM structure of WT human ZnT-8 in the absence of  $Zn^{2+}$  (PDB code: 6XPF,<sup>34</sup> light purple), where each monomer adopts a different conformation; the  $Zn^{2+}$  ions are presented as yellow spheres, whereas the  $S_{TM}$ ,  $S_{IF}$  and  $S_{CDs}$  sites are marked in blue. Right: both human ZnT structures overlapped onto each other, displaying the different conformation of one of the TMD monomers. (D) Detailed high magnification of  $S_{TM}$ ,  $S_{IF}$  and  $S_{CDs}$   $Zn^{2+}$  binding sites of WT human ZnT-8 in the  $Zn^{2+}$ -bound state.  $Zn^{2+}$  ions are presented in yellow and the coordination first-shell residues are presented as sticks. The superscript 2 and the red color mark the second monomer. All structural figures were produced using the UCSF Chimera package, version 1.12.<sup>106</sup>

CDF proteins, a metal binding site exists in all characterized CTD-containing CDFs. The two symmetrical equivalent bacterial CTD C-sites in ZnT-8 ( $S_{cd}$  sites) are less defined and their cation-bound geometries are far from optimal due to the low resolution cryo-EM map. These sites contain four  $Zn^{2+}$  cations as well, which are bound by a network of residues from both monomers.<sup>34</sup> Only one of the YiiP symmetrical C-sites'  $Zn^{2+}$  ions overlaps onto that of ZnT-8 ( $S_{cd2}$  site).

## The mechanism of the cytoplasmic domain

The CTD can be considered an activator/regulator of the transport. This is supported by the decreased or abolished activity of CDFs by CTD deletion or mutations.<sup>38,40,42–48</sup> In humans, it may also lead to the development of diseases.<sup>23,49</sup> In the bacterial CDFs ZitB and YiiP, the removal of  $Zn^{2+}$  from




the CTD binding sites led to protein precipitation,<sup>35,50</sup> suggesting that  $Zn^{2+}$  binding has a role in protein folding or protein structural stabilization. However, the importance of this domain in the context of overall folding and stabilization is not clear yet as its misfolding in another bacterial protein, MamM, does not completely abolish the transport.<sup>51</sup>

In all YiiP and ZnT-8 structures the CTD adopts the same closed conformation due to the presence of zinc (Fig. 1A and C). Hence, to examine the impact of the binding of DDMCs and to follow the conformational space, crystal structures and biophysical studies of CTDs of other CDFs are needed. Currently, it was achieved mainly by utilizing bacterial proteins.<sup>40,41,52,53</sup> The CTDs of CDFs form a V-shaped dimer, with each monomer adopting a copper metallochaperone-like (Hah1) fold.<sup>36,38,40,41,43,54,55</sup> When comparing the CTD structures of different CDFs,<sup>36,38,40,41,43,53,54</sup> it appears that it can have different degrees of openness in the apo and bound states (Fig. 2A and B, respectively). This implies that the V-shaped arms are dynamic.<sup>52</sup> Still, the crystal structures of the bacterial CDF proteins CzrB, CzcD and MamM

show that the monomers are approaching each other to form a tighter DDMC-bound conformation as compared to the apo conformation<sup>41,53,56</sup> (Fig. 2C and D). This was further confirmed by the biophysical studies of full YiiP<sup>38</sup> and CTDs in solution, which revealed a final rigid bound state.<sup>40,41,52,53</sup> Hence, it is conceivable that the CTD-bound DDMCs, rather than sequentially transported, remain bound and play a role in closed conformation stabilization (as will be discussed below).

The C-site is not conserved among CDF proteins as was already described above for ZnT-8 (see Fig. S1, ESI† for sequence data). For example, both  $Zn^{2+}$ -transporting CDF proteins CzrB and YiiP have partially different CTD binding sites (Fig. 2B and C),<sup>36,38,41</sup> and for CzcD a single  $Ni^{2+}$  site was found in *Cupriavidus metallidurans*, two sites in *Pseudomonas aeruginosa* and a single  $Zn^{2+}$  site in *Thermotoga maritima*.<sup>56</sup> MamM CTD possesses a central binding site and two symmetrical peripheral metal binding sites which are homologous to one of the YiiP and CzrB symmetrical  $Zn^{2+}$  binding sites (Fig. 2B and D).<sup>40,52,53</sup> In contrast, the bacterial CDF MamB has only a



**Fig. 2** The structures and suggested  $Zn^{2+}$  binding mechanism of the CTDs of CDF proteins. (A) Apo CTD structures of CzrB (PDB code: 3BYR,<sup>41</sup> pink), MamM (PDB code: 3W5X,<sup>40</sup> purple), MamB (PDB code: 5HO5,<sup>43</sup> yellow) and TM 0876 from *Thermotoga maritima* (PDB code: 2ZZT,<sup>54</sup> orange) overlapped onto each other. (B) Bound CTD structures of CzrB with  $Zn^{2+}$  (PDB code: 3BYR,<sup>41</sup> light pink), MamM with  $Cu^{2+}$  (PDB code: 6GP6,<sup>53</sup> light purple), MamB with  $Zn^{2+}$  (PDB code: 5HO1,<sup>43</sup> light yellow), EcYiiP with  $Zn^{2+}$  (PDB code: 3H90,<sup>38</sup> light green) and SoYiiP with  $Zn^{2+}$  (PDB code: 5VRF,<sup>36</sup> light blue) overlapped. In each structure, the DDMCs are presented as enlarged spheres in the proteins' colors. (C) The apo (dark pink) and  $Zn^{2+}$ -bound (light pink) structures of CzrB CTD and (D) the apo (dark purple) and  $Cu^{2+}$ -bound (light purple) structures of MamM CTD show the tighter conformation of the CTD that is achieved due to DDMC binding. The DDMCs are presented in yellow color and binding site residues are presented as sticks. (E)  $Zn^{2+}$  binding mechanism of MamM CTD (the model is adopted from Barber-Zucker *et al.*,<sup>52</sup>  $Zn^{2+}$  ions are presented as yellow spheres). Rapid  $Zn^{2+}$  binding (<1 microsecond) to the dynamic apo form's central site results in a minor conformational change but has an allosteric positive effect on the binding to the peripheral sites. Only slower (millisecond time scale) binding of two ions to the symmetrical sites causes a closure of the CTD to a tighter, rigid V-shape.



central binding site.<sup>43</sup> Interestingly, while MamM and CzcB exhibit different conformations in the apo and bound structures, MamB-bound and apo structures have very similar conformation.<sup>40,41,43,53</sup> This might be due to the periphery binding site that leads to dimer closure (the site is conserved in MamM, YiiP and CzcB but is not found in MamB). This is supported by MamM CTD kinetic and mechanistic studies (Fig. 2E): rapid Zn<sup>2+</sup> binding to the central site resulted in a minor conformational change but has an allosteric positive effect on the binding to the peripheral sites. Only binding of two ions to the symmetrical sites causes closure of the CTD to a tighter, rigid V-shape.<sup>52</sup> However, the structural study of MamM CTD in the presence of different DDMCs showed that the binding of a given DDMC to this domain has unique affinity and conformation<sup>53</sup> (which indicate a role in metal selectivity, as will be discussed below). Hence, the observed varied CTD conformations might be relevant only to the specific DDMC under study. The suggested mechanism of CDF activation *via* CTD closure following the appropriate DDMC binding is well supported by the binding affinities. Measurements of metal binding to purified CTDs showed similar dissociation constants (ranging from ~2 to 30 μM<sup>52,56</sup>), which indicate a greater affinity to the TMD site ( $K_d \sim 0.1\text{--}1 \mu\text{M}$ <sup>57</sup>). These affinities suggest a CTD closed state and TMD transition activation only after the cytosolic metal concentrations reach relatively high values. Such transition was monitored *via* the molecular dynamics simulation of YiiP.<sup>58</sup> Once the TMD is open, its metal transport site achieves a much higher affinity, thus enabling metal binding and transport through the TMD. When the cytosol metal concentration drops below the CTD affinity, the CTD will convert to the open state, leading to metal transport termination. In contrast to these conformational changes, ZnT-8 (and due to conservation, putatively also ZnT-2 and ZnT-3, see Fig. S1, ESI<sup>†</sup>) is constantly stabilized at a closed CTD conformation as a result of an additional HCH (His52-Cys53-His54) motif at the N-terminus of the neighboring ZnT-8 subunit, which seals the Zn<sup>2+</sup> binding sites and prevents cation dissociation.<sup>34</sup> This indicates that ZnT-8, a known secretory-organellar CDF, together with ZnT-2 and ZnT-3, resides within the cell<sup>8</sup> and most likely competes with ZnT-1 (a cytoplasmic-membrane CDF that extrudes Zn<sup>2+</sup>) on the same cation and needs to be in a constant active state.

## The conformational space of the full CDF proteins

The YiiP cryo-EM and X-ray structures exhibit two different TMD conformations: the inward facing conformation provides A-site access from the cytoplasm, while the outward facing conformation provides A-site access from the periplasm.<sup>35–38</sup> Surprisingly, the structure of WT ZnT-8 in the absence of Zn<sup>2+</sup> yielded a heterogeneous conformation, with one subunit in an inward-facing and the other in an outward-facing conformation.<sup>34</sup> The YiiP structures suggest a TMD scissor-like motion between the two states (Fig. 1A). The conformations

of the monomers differ in the TMH1,2,4,5 bundle that surrounds the A-site, which rocks against TMH3 and 6. Additionally, TMH2 and 5 form longer helices and bend near the A-site in the inward facing conformation (Fig. 1A and 3).<sup>36</sup> An EcYiiP X-ray mediated hydroxyl radical labeling and its MD simulation revealed that Zn<sup>2+</sup> access to the A-site in EcYiiP is controlled by the leucine residue (L152) found in the TMH5 cytosolic side and serves as a hydrophobic gate. This means that the movement of this helix is crucial for both proper zinc chelation and A-site access.<sup>58,59</sup> Nevertheless, the A-site in both conformations is similarly populated in terms of the coordination geometry.<sup>36</sup> Investigating the TMD dimerization, the EcYiiP structure shows almost no contact and a gap between the TMDs that becomes wider in the periplasmic side, while the TMDs of SoYiiP are much closer (Fig. 1A). The crosslinking between SoYiiP TMH3 residues did not lead to a decrease in transport activity. This suggests a tighter packing of the TMD with intact TMHs 3 in all states, in contrast to EcYiiP with an outward facing conformation, and that conformational changes within each monomer are functionally sufficient. There are two plausible explanations to the observable TMD conformation of EcYiiP: the use of detergent micelles, which behave differently than the lipid bilayer used in the SoYiiP cryo-EM studies (comparison of the TMD packing of the crystal and the cryo-EM structures demonstrates some destabilization effects of the detergent environment that can facilitate the separation of TMDs, maybe by recruiting detergents to stabilize each monomer individually), or separation due to crystal packing (the asymmetric unit in the crystals contains two sets of dimers; in each intramolecular contacts through the outer surface of the TMD are observed, which seem to hold the TMDs



**Fig. 3** The different conformations of monomeric TMDs of YiiPs. YiiP TMD monomers (EcYiiP, PDB code: 3H90,<sup>38</sup> in light green, and SoYiiP, PDB code: 5VRF,<sup>36</sup> in light blue) overlap onto each other, showing the movement of TMH1,2,4,5 with respect to TMH3,6 in the transition between the inward facing (SoYiiP) and outward facing (EcYiiP) conformations. The Zn<sup>2+</sup> ions are presented in the protein's darker colors.





**Fig. 4** Suggested mechanism for the conformational changes associated with the binding of DDMCs to CDF proteins. Left: At rest, the TMD (SoYiiP ribbon, PDB code: 5VRF<sup>36</sup>) is found in the inward facing conformation and the CTD (CzrB apo structure ribbon, PDB code: 3BYP<sup>41</sup>) in an apo, open V-shaped form. Middle: when the metal concentration in the cytoplasm is sufficiently high, the DDMCs are bound to the CTD, which leads to its closure to a tighter V-shaped conformation (SoYiiP ribbon, PDB code: 5VRF<sup>36</sup>). Right: The closure of the CTD is assumed to facilitate the TMH1,2,4,5 bundle movement relative to TMH3 and 6, leading to the outward facing conformation, which allows the DDMC to be extruded and the counter-ion to be bound onto the A-site (the model of EcYiiP outward facing conformation adopted from Lopez-Redondo *et al.*<sup>36</sup>). TMD is represented in blue, CTD in purple, DDMCs in enlarged yellow spheres and counter-ions in green.

apart and influence the rigidity of the TMD helices in the contact surface).<sup>36</sup>

The communication between the domains is also crucial for the overall protein mechanistic understanding. The TMD–CTD connecting loop in YiiP is salt-bridged *via* aspartate to the TMH2-3 loop. It was previously suggested that this charge interlock is the linking hinge between the CTD conformational change and the TMD.<sup>36,38,39,44</sup> However, the aspartate is not conserved among all CDFs and the SoYiiP study suggests a TMH1,2,4,5 bundle movement relative to the static TMH3 and 6 and not a scissor-like motion.<sup>36</sup> Hence, it is still not clear what is the exact role of the charge interlock and whether a hinge-like motion can facilitate the TMD conformational change.

Taken together, these structural data are consistent with the predicted mechanism that CTD metal binding facilitates the TMD conformational change and allows the DDMC transport<sup>36,39,40</sup> (Fig. 4). At rest, the TMD is found in the inward facing conformation and the CTD in an apo, open V-shaped form. When the cytoplasmic metal concentration is sufficiently high, the DDMCs are bound to the CTD, leading to its closure to a tighter V-shaped conformation. The rigid closure of the CTD is assumed to facilitate, maybe through a charge interlock, the TMH1,2,4,5 bundle movement relative to TMH3 and 6. This allows the A-site to face the periplasm/inner-cellular component and the DDMC to be extruded.<sup>36,39,40,58</sup> During the active transport, the tight CTD packing remains static, while the rocking movement of the TMD bundles facilitates the antiporter activity.

## Metal selectivity by CDF proteins

While the structural studies of the bacterial CDF proteins led to a better understanding of the function of CDFs, the mechanism of their metal selectivity remained unclear. For example, EcYiiP

shows both Zn<sup>2+</sup> and Cd<sup>2+</sup> efflux abilities (Zn<sup>2+</sup>:  $K_{0.5} \sim 554 \mu\text{M}$ ,  $V_{\text{max}} \sim 20 \text{ s}^{-1}$ ; Cd<sup>2+</sup>:  $K_{0.5} \sim 0.27 \mu\text{M}$ ,  $V_{\text{max}} \sim 14.4 \text{ s}^{-1}$ ).<sup>38,57</sup> Many studies on CDFs from different phyla show the binding and transport of a specific DDMC or DDMCs.<sup>7,39</sup> For example, the CDF phylogenetic classification has divided them into 17 clades that play a role in the transport of specific DDMCs.<sup>7</sup>

Most CDF metal selectivity studies concentrate on the structurally conserved A-site composition (Fig. 1B, Fig. 5 and Fig. S1, ESI<sup>†</sup>). It is composed of four metal-binding residues (quartet), usually a combination of histidine and aspartate residues.<sup>39,60,61</sup> Numerous studies examined the relationship between the A-site composition and metal selectivity. They showed that deletion (alanine) mutations in this site decrease the transport activity and that changes in the quartet composition (so it is composed of non-native metal binding residues) abolish or enhance specific metal transport.<sup>10,12,13,39,43–46,61,62</sup> For example, ZnT-10, with the ND-HD quartet, is selective for Mn<sup>2+</sup>, while changing the HD-HD quartet in ZnT-1 to ND-HD also changed its selectivity from Zn<sup>2+</sup> to Mn<sup>2+</sup>.<sup>10,63</sup> An analysis of DDMC binding sites was used to examine whether the A-site can solely dictate metal selectivity and whether there is a correlation between the CDF phylogenetic classification<sup>7</sup> and their metal selectivity.<sup>60,61</sup> This study showed that the A-site composition does not solely determine the metal selectivity.<sup>60</sup>

Other CDF features such as extra loops and special sequence composition were also studied (Fig. 5), but these features were specific to a given protein or were studied on a rather small number of proteins, thus not allowing generalized conclusions. For example, a cytoplasmatic Histidine-rich loop (HRL) between TMH4 and 5 in *Arabidopsis thaliana* MTP1 protein is related to Zn<sup>2+</sup>-binding and specificity.<sup>32,64–66</sup> Similarly, the HRLs of some human ZnTs have also been suggested to play a role in specific metal chelation.<sup>13,67</sup> In a class of CTD-lacking CDFs, it is suggested that the cytoplasmatic N-terminal tail, a domain rich in cysteine, aspartate, glutamate and histidine





Fig. 5 The X-ray structure of YiiP (PDB code: 3H90<sup>38</sup>) with features related to metal selectivity highlighted in red. The TMH4-5 loop in YiiP is shorter than regular His-rich loops and it has a short NTD; hence, these features are drawn elongated for clarity. The locations of Zn<sup>2+</sup> ions in the structure are presented as enlarged yellow spheres.

residues, can chelate metals and hence may play a role in metal selectivity.<sup>39</sup> Consistent with this notion, an MTP1 extended N-terminal deletion has a different Zn<sup>2+</sup> transport capability compared to Cd<sup>2+</sup> or Co<sup>2+</sup>, supporting its role in metal chelation and selectivity.<sup>66</sup> Its ability to sense the cytoplasmic environment supports the notion that the CTD plays a role in metal selectivity. Indeed, recent MamM CTD structural studies show that each DDMC has different binding affinity and conformation.<sup>53</sup> Furthermore, mutations to alternative DDMC-binding residues in MamM CTD changed its ability to bind with specific DDMCs, and some mutant-DDMC pairs exhibit different conformations than the wildtype-DDMC.<sup>68</sup> Altogether, these studies demonstrate the C-site role in metal selectivity.

## CDF proteins are antiporters with diverse counter-ions

For many CDF proteins from bacteria,<sup>35,47,50,69–72</sup> yeasts,<sup>73</sup> plants<sup>65</sup> and humans,<sup>12,33,74,75</sup> the DDMC transport depends on the pH gradient. X-ray-mediated hydroxyl radical labeling of EcYiiP demonstrated that the pH is responsible for protonation of one of the A-site histidine residues (H153) at the outward facing conformation, suggesting that the pH gradient drives a unidirectional efflux of zinc in a 1:1 ratio with protons.<sup>59</sup> However, A-site histidine residues are not found in all CDFs;<sup>60</sup> thus, this zinc/proton exchange mechanism cannot be applied to all. For example, *Bacillus subtilis* CzcD can catalyze Zn<sup>2+</sup> efflux in exchange for proton and potassium ions.<sup>70</sup> Furthermore, ZnT-10 was characterized as a Mn<sup>2+</sup>/Ca<sup>2+</sup> exchanger

( $K_{0.5} \sim 973 \mu\text{M}$ ,  $V_{\text{max}} \sim 1.234 \text{ s}^{-1}$ ).<sup>10</sup> The A-site quartet of ZnT-10 is ND-HD; it seems as if this composition, and specifically the substitution of histidine from the HD-HD quartet in other ZnTs to asparagine, was evolutionarily tailored for the specific binding of both Mn<sup>2+</sup> and Ca<sup>2+</sup> while excluding Zn<sup>2+</sup>.<sup>10</sup> These results suggest that the A-site plays a role in DDMC selectivity and in counter-ion selection.

## Structural perspective on ZnT-related diseases

The limited knowledge of the structures of eukaryotic CDFs depends on ZnT-8 structures, and biochemical studies of plant MTPs and human ZnTs all indicate that the eukaryotic CDFs share the basic components of prokaryotic CDFs. Both the TMD and CTD have similar structures and locations of metal binding sites, although they vary in their sequences.<sup>10,33,34,66,74</sup> However, eukaryote CDFs include additional cytoplasmic domains and loops that seem to add regulation (Fig. 5). The HRL (not resolved in the ZnT-8 cryo-EM map) contributes to the CDF activity as demonstrated by reduced activity or inactivity following histidine-to-alanine mutations or deletion of the extended loop.<sup>76</sup> Surprisingly, the replacement of ZnT-1 HRL with ZnT-10 HRL led to the restoration of zinc resistance although the latter does not contain any histidines.<sup>63</sup> In the plant Co<sup>2+</sup>/Zn<sup>2+</sup>-CDF MTP1 ( $K_{0.5} \sim 0.3 \mu\text{M}$ ,  $V_{\text{max}} \sim 1.2 \text{ s}^{-1}$ ), the HRL (80 amino acids) binds both Co<sup>2+</sup> and Zn<sup>2+</sup> and mutations change its cation specificity,<sup>66</sup> while its removal leads to a 2–11 fold rate increase.<sup>65</sup> The NTD is also important for the activity as its deletion reduces or abolishes the transport.<sup>34</sup> In ZnT-8, the NTD contains an HCH motif that participates in metal binding and keeps the CTD in a closed conformation. Deletion of the HCH abolished the transport, most likely due to the loss of regulation by the CTD.<sup>34</sup> The data obtained on ZnT-4 suggested that the NTD participates in protein–protein interactions.<sup>77</sup> Moreover, domain swap of the NTD and the HRL between ZnT-2 and ZnT-3 showed that mixed NTD and HRL inactivate both CDFs, while replacing both domains led to fully functional CDFs.<sup>76</sup>

Surprisingly, not many ZnTs' disease-causing mutations are described in the literature although ZnT proteins are highly important for proper cell function. This may be due to the fact that ZnT mutations are lethal. A better understanding of the disease mechanism requires structural knowledge of wildtype and mutants which is not yet available for most ZnT-related diseases. Here we summarize those that were studied in the context of ZnT-related diseases in terms of how these mutations may affect the structure and function of ZnT proteins.

### ZnT-2

ZnT-2 is found in the mammary glands, and its mutations in mothers lead to poor secretion of zinc into breastmilk, leading to zinc deficiency in breastfed babies. The mutations H54R,<sup>19</sup> G87R,<sup>78</sup> S296L, W152R,<sup>49</sup> G280R, T312M and E355Q<sup>79</sup> in ZnT-2 (Fig. 6), as well as H106Y, R165W, G175W, N214K, G233D/R, P245R, E279K, G299W and V300L,<sup>20</sup> were associated with





**Fig. 6** The X-ray structure of YiiP (PDB code: 3H90<sup>38</sup>) with ZnT disease-causing mutations marked on their predicted approximate locations. Mutations in ZnT-2 are marked in blue, in ZnT-3 in pink, in ZnT-8 in orange, in ZnT-9 in yellow and in ZnT-10 in green. YiiP has a short NTD and hence it was drawn elongated for the inclusion of the ZnT-2 H54R mutation. Lower right panel: the CTD of the human ZnT-8 structure (PDB code: 6XPD<sup>34</sup>) with R325 residues presented as orange sticks.

transient neonatal zinc deficiency and we will discuss some of them below. In newborns, the observed Zn<sup>2+</sup> deficiency may lead to diarrhea, loss of appetite and the development of dermatitis.<sup>17</sup> The ZnT-2 model based on the YiiP X-ray structure enabled a better understanding of the mechanism of its mutations.<sup>17,19,78</sup> H54R is assumed to be located at the unstructured NTD of ZnT-2.<sup>19</sup> Since this tail was suggested to play a role in metal chelation and selectivity, and as histidine frequently chelates DDMCs, it might be that this mutation decreases Zn<sup>2+</sup> recruitment and consequently leads to failure to increase the local zinc concentration needed to activate ZnT-2. G87R is found in TMH1 facing the membrane and it was suggested that this dramatic substitution, from a small glycine to the bulky charged arginine in the membrane environment, will cause improper folding and might lead to the observed low expression level and ZnT-2 subcellular localization alteration.<sup>78</sup> In contrast, S296L is localized to the CTD surface and thus does not cause any significant structural change. Therefore, it enables moderate Zn<sup>2+</sup> transport and is probably responsible for the observed fast protein degradation. As S296 is predicted to undergo phosphorylation, it is suggested that phosphorylation impairment is the underlying mechanism for the mutant functional impairment. G280R is located on the TMD–CTD connecting loop and impairs vesicular Zn<sup>2+</sup> transport. The substitution from the small glycine to the bulky charged arginine was suggested to interfere with the Zn<sup>2+</sup> permeation pathway.<sup>79</sup> However, this steric interference can also interrupt the cross-talk between the domains and hence the CTD regulation, leading to a decrease in transport activity. E355Q,

part of the CTD Zn<sup>2+</sup> binding site (C-site), abolishes the transport activity and disrupts the protein cellular localization.<sup>79</sup> As glutamate is much more abundant in Zn<sup>2+</sup> binding sites compared to glutamine,<sup>60</sup> this mutation can reduce Zn<sup>2+</sup> binding to the CTD and its related conformational change, which will not allow TMD transport regulation, thus, will cause a loss of function and observed phenotypes. Recently, a new mutation set was found in ZnT-2: H106Y, R165W, G175W, N214K, G233D/R, P245R, E279K, G299W and V300L.<sup>20</sup> The structural model of ZnT-2 indicates that many of these residues might cause structural changes. These include steric collisions (E279K, G299W and V300L), charge repulsion (N214K and E279K), changes in loop flexibility (G175W), hydrophobicity alterations (G233D/R), breaking of ion chelation (H106Y), and breaking of the possible salt bridge (R165W). Not surprisingly, many of these positions are highly conserved, most likely due to their structural importance.

### ZnT-3

ZnT3 is responsible for Zn<sup>2+</sup> transport into synaptic vesicles, where it is co-localized with glutamate and released in an activity-dependent manner. Synaptic zinc levels are associated with neuronal excitability and seizure susceptibility, as extracellular zinc interacts with many ion channels, receptors and transporters.<sup>80,81</sup> The R298C mutation in ZnT-3 is related with febrile seizures, with the mutant protein being dysfunctional due to subcellular mislocalization.<sup>81</sup> It was previously shown that the correct ZnT-3 subcellular localization relates to its homodimerization and that the CTD is important for its dimerization.<sup>82</sup> As this mutation is predicted to be in the CTD, it was suggested that it destabilizes ZnT-3 homodimerization.<sup>81</sup> The sequence alignment of ZnT-3 and other modeled ZnTs suggests that R298 is either in the C-terminal of the TMD–CTD connecting loop or in the N-terminal of the first CTD helix. However, this region does not relate to the CTD dimerization (Fig. 6). The native arginine can form multiple bond types with nearby residues which are limited by the smaller cysteine. Therefore, based on the substitution nature and the predicted location, we suggest that the mutation disrupts the cross-talk between the domains. However, we cannot explain why it impairs protein localization and more molecular and structural studies are needed to elucidate the mechanism of this mutation.

### ZnT-8

ZnT-8 is highly expressed in pancreatic beta cells, where it is responsible for transporting zinc into insulin granules and by that enabling crystalline insulin packing within them (due to the formation of stable complexes of insulin hexamers with zinc).<sup>83</sup> The most structurally characterized ZnT disease-related SNP is the W325R variant in ZnT-8 which is associated with an increased risk of developing type-2 diabetes. This variant is located at the tip of the V-shaped CTD dimer (near the dimer interface, Fig. 6).<sup>28,29,42</sup> Kinetic studies of purified ZnT-8 in proteoliposomes showed that the R325 variant exhibits accelerated zinc transport activity as compared to the W325 variant.<sup>28</sup> As ZnT-8 loss-of-function mutations (protein truncating variants and frameshift variants that are predicted to improperly fold into



the membrane) were shown to better protect against type-2 diabetes, this study suggests that the R325 variant is hyperactive.<sup>28,84</sup> The W325R substitution had no effect on the expression, stability and subcellular localization of ZnT-8 in HEK293 cells. Since secretory granules store very high levels of zinc compared to the cytoplasmic free-zinc concentration, it might be that this enhanced difference in the R325 variant reverses the ZnT-8-mediated transport to extrude zinc from the granules. However, more studies are required to fully understand how this substitution impacts the ZnT-8 function, zinc homeostasis in the cellular level and the increased risk for type-2 diabetes.<sup>28</sup> In terms of structural differences between the variants, ZnT-8 CTD biophysical studies showed that both variants have similar secondary structures, but that the W325 variant is less thermostable. Yet, its monomers are associated into a dimer with a higher affinity. It further showed that both variants can similarly bind Zn<sup>2+</sup>.<sup>29,33</sup> The structure of ZnT-8 was determined only for the R325 variant and, as such, the exact effect of the W325 variant is yet to be determined, especially as it is located on the protein surface.<sup>34</sup>

### ZnT-9

ZnT-9 is moderately expressed in most tissues, while in the cerebellum, fetal brain, kidneys and skeletal muscle it is highly transcribed. The ZnT-9 A350del mutation, which is located at TMH4 (Fig. 6) and decreases ZnT-9-dependent Zn<sup>2+</sup> transport, is related to a cerebro-renal syndrome.<sup>11</sup> The TMD helical residue deletion is assumed to cause disorientation of the helix terminal. It either forms a shorter helix that will increase the TMH4 tension and deform its structure, or force a loop residue to be inserted, forming a longer helix that still fits into the membrane. In any case, the mutation may lead to changes in interactions between the TMD residues, and protein-lipids, leading to structural destabilization of the A-site and the whole domain. This proposed structural change is further strengthened by the Zn<sup>2+</sup> transport activity impairment observed *in vitro*.<sup>11</sup> Since zinc has a significant role as a signaling mediator and in brain development and proper function in all stages of life, the impairment in zinc homeostasis is thought to be the cause for the phenotypic effects of the A350del mutation.<sup>11,85</sup>

### ZnT-10

ZnT-10 is a manganese transporter expressed mainly in the brain and liver, and located in endosomes, the Golgi apparatus and the cell membrane.<sup>10,86,87</sup> The ZnT-10 L349P mutation causes hypermanganesemia, hepatomegaly and dystonia.<sup>23</sup> Structural characterization, through MamM CTD,<sup>51</sup> predicts its location in the middle of the  $\beta$ -sheet central  $\beta$ -strand of the CTD (Fig. 6). The MamM homologous mutation M250P causes complete CTD structural loss, which leads to a low expression level compared to wildtype and a decrease in function. Overall, this mutation caused protein degradation *via* improper CTD fold and recruitment of proteases.<sup>51</sup> Since non-degraded MamM proteins showed some activity and ZnT-10 mutation is not lethal, it is suggested that the unstructured

CTD, which contains the DDMC binding residues, can still facilitate the TMD conformational change. This leads to inefficient ZnT-10-mediated Mn<sup>2+</sup> extrusion and its accumulation in the cells and the resultant phenotypes, which are expected physiological consequences of impairment in manganese homeostasis.<sup>51</sup>

Some other mutations in ZnT-10 cause hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia, among which are L89P (predicted to be in TMH3), A105-P107del (predicted to be on the loop between TMH3 and TMH4) and V256del (predicted to be in TMH5)<sup>23</sup> (Fig. 6). Similarly to the L349P mutation in ZnT-10, and since proline destabilizes secondary structures, we suggest that the L89P deforms TMH3. This will destabilize the TMD in a way that at worst might result in full protein misfolding. In any case, the location in TMH3 will impact Mn<sup>2+</sup> transport by changing the rocking movement and dimerization alteration. The A105-P107del will lead to a shorter TMH3-TMH4 connecting loop and we predict that the loop length is essential for a proper rocking movement. Hence, this mutation will also impact the transition between the inward and outward conformations. The ZnT-10 256 position is found in the TMH5 C-terminal, in a region that might be unstructured, yet it is part of a hydrophobic chain predicted to be buried in the membrane. Hence, we assume that it will have an effect similar to the A350del mutation in ZnT-9. It will cause more tension in the membrane and will change the interaction networks between the TMD residues themselves and with the lipids, leading to destabilization of the whole domain.

## ZnT-1 as an example for multiple functions of ZnT proteins

ZnT-1 (SLC30A1) is the most abundantly expressed member of the mammalian CDF family and is involved in Zn<sup>2+</sup> homeostasis.<sup>12,48,88–91</sup> The ZnT-1 expression increases following transient forebrain ischemia,<sup>92</sup> rapid cardiac pacing, an exposure to high, nontoxic, levels of Zn<sup>2+</sup>,<sup>24,25,27</sup> and also increases in dietary Zn<sup>2+</sup>.<sup>88</sup> ZnT-1 induction is mediated by the metal regulatory transcription factor 1 (MTF-1),<sup>88,93,94</sup> which, besides increasing in response to extracellular Zn<sup>2+</sup>, is activated by an increase in intracellular Ca<sup>2+</sup>.<sup>95</sup> In addition, MTF-1 is activated by oxidative stress.<sup>96</sup> Some of these stimuli probably underlie the observed increase in ZnT-1 expression in conditions such as rapid pacing or ischemia-reperfusion in the heart.<sup>27,97</sup> ZnT-1 protects against zinc toxicity due to its Zn<sup>2+</sup> extruder activity.<sup>12,48,98</sup> ZnT-1 knockout is embryonically lethal<sup>88,93,99</sup> even when there is no significant exposure to systemic Zn<sup>2+</sup>. This implies that, even when its Zn<sup>2+</sup> extrusion function is not needed acutely, ZnT-1 plays other critical roles in development and cellular function. These findings may explain why no ZnT-1-related mutation has been identified although sequence variations were found in the genome databases.

Being a member of the CDF family, ZnT-1 is responsible for cellular activity that reduces zinc toxicity.<sup>98</sup> However, as implied



by the lethality of the knockout, ZnT-1 plays another important role: a modulator and an integrator of signaling and cation channel function. In addition, ZnT-1 activates signaling molecules including ERK through Ras-mediated signaling.<sup>24,27,100,101</sup> Furthermore, ZnT-1 inhibits Zn<sup>2+</sup> and Ca<sup>2+</sup> influx by inhibiting L-type Ca<sup>2+</sup> channels.<sup>26,89,97,102</sup> In yeast two-hybrid experiments, ZnT-1 interacts with another channel, the calcium homeostasis ER protein (CHERP).<sup>103–105</sup> All of these activities of ZnT-1 are independent of its function as a Zn<sup>2+</sup> transporter as they are also mediated by ZnT-1 CTD itself.<sup>24,27,98</sup> This observation is consistent with the embryonic lethality of the knockout.

## Concluding remarks

A structure–function investigation of CDFs is highly important for elucidating the underlying mechanism of many diseases associated with them. A remarkable advancement in recent years unraveled key features for metal binding and conformational changes. The structural and biophysical studies of YiiP and ZnT-8 unveiled the cation binding sites and some TMD conformations, while the studies of the CTDs of other bacterial CDFs facilitated their functional understanding. These studies allow better insights into the overall CDF transport mechanism. Based on the recent structural data, it is clear that the mechanism of mammalian ZnTs is similar to that of bacterial CDFs. Yet, eukaryotic CDFs evolved to include additional domains that attenuate the basic transport function existing in bacteria and provide additional activities. The current knowledge from CDFs in prokaryotes and eukaryotes allows a better interpretation of ZnT-related diseases. Current mutations underlying the observed phenotypes in mammals are mostly located on the basic CDF structure, found also in the bacterial domains (TMD and CTD), indicating that the basic transport mechanism is conserved through evolution. Yet, since the eukaryote CDFs play additional roles and act in more complex environments, some of the current mutations affect subcellular localization, signaling and stability and indirectly affect the transport efficiency.

Significant progress in the structural studies of CDF proteins contributed a lot to their mechanistic understanding. Yet, there are still many unknown factors that prevent us from achieving a complete understanding, such as the apo conformation of the full proteins and the difference in affinities between the CTD and TMD DDMC binding sites, which are of utmost importance for deciphering the DDMC path along the protein. Moreover, as some eukaryotic elements, such as elongated NTD and the HRL, were not characterized through the studies of bacterial CDF proteins, it is essential to study several eukaryotic CDFs to achieve a complete understanding of their structure and function and their contribution to the transport mechanism.

Metal selectivity is an additional mystery in CDF studies. To date, we are far from understanding what governs the metal selectivity of CDFs. To that end, the CDF A-site is the most characterized element, and it is believed that DDMC binding

and selectivity in most CDF proteins can be controlled by means of its amino acid composition. However, some studies showed that this is not the sole determinant and other elements may contribute to metal selectivity. Unfortunately, these studies did not explore the binding capabilities to all DDMCs, neither did they involve deep structural analysis. Since not all CDF proteins discriminate similarly among the DDMCs, only biophysical investigation of the metal-selectivity related elements in many CDF proteins will allow a significant step towards elucidating an overall metal selectivity mechanism. Additionally, the metal acquisition of CDF proteins is unknown. The cytosolic concentrations of many metals, including zinc, are very low and consequently their availability to a CDF protein by free diffusion is low. This supports the speculation that a specific metallochaperone is recognized by CDFs and facilitates metal transfer and transport activation.

In conclusion, despite the enormous progress in the study of various CDFs, there is still a lot to be found before achieving a complete understanding of the entire CDF conformational space. Thus, complete ZnT structure–function relationship and mechanism studies are still needed. Hopefully, as done for other proteins and recently with ZnT-8, cryo-EM or XFEL will soon revolutionize the study of CDFs, with an aim to achieve a deeper understanding of CDFs in general and of ZnTs specifically, paving a way for the development of ZnT-targeted drugs for the treatment of CDF-related diseases.

## Author contributions

All authors were involved in data curation, writing of the original draft, review and editing.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

We would like to thank Prof. David L. Stokes for providing the PDB file of the tighter TMD dimerization model of EcYiiP. The authors are supported by the Israel Ministry of Science, Technology and Space, the Israel Science Foundation (grant no 167/16), the European Molecular Biology Organization and CMST COST Action CM1306.

## References

- 1 T. J. Lyons, D. J. Eide and V. Introduction, in *Biological inorganic chemistry: structure and reactivity*, ed. I. Bertini, H. Gray, E. Stiefel and J. S. Valentine, University Science books, CA, USA, Transport and Storage of Metal Ions in Biology, 2006, pp. 57–78.
- 2 Y. Lu, *Inorg. Chem.*, 2006, **45**, 9930–9940.
- 3 M. M. Harding, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2004, **60**, 849–859.



- 4 T. Dudev and C. Lim, *Chem. Rev.*, 2014, **114**, 538–556.
- 5 H. Irving and R. J. P. Williams, *Nature*, 1948, **162**, 746–747.
- 6 C. J. Haney, G. Grass, S. Franke and C. Rensing, *J. Ind. Microbiol. Biotechnol.*, 2005, **32**, 215–226.
- 7 C. Cubillas, P. Vinuesa, M. L. Tabche and A. García-de los Santos, *Metallomics*, 2013, **5**, 1634–1643.
- 8 L. Huang and S. Tepasamordech, *Mol. Aspects Med.*, 2013, **34**, 548–560.
- 9 P. Chen, A. B. Bowman, S. Mukhopadhyay and M. Aschner, *Worm*, 2015, **4**, e1042648.
- 10 M. Levy, N. Elkoshi, S. Barber-Zucker, E. Hoch, R. Zarivatch, M. Hershfinkel and I. Sekler, *J. Biol. Chem.*, 2019, **294**, 5879–5889.
- 11 Y. Perez, Z. Shorer, K. Liani-Leibson, P. Chabosseau, R. Kadir, M. Volodarsky, D. Halperin, S. Barber-Zucker, H. Shalev, R. Schreiber, L. Gradstein, E. Gurevich, R. Zarivach, G. A. Rutter, D. Landau and O. S. Birk, *Brain*, 2017, **140**, 928–939.
- 12 E. Shusterman, O. Beharier, L. Shiri, R. Zarivach, Y. Etzion, C. R. Campbell, I. H. Lee, K. Okabayashi, A. Dinudom, D. I. Cook, A. Katz and A. Moran, *Metallomics*, 2014, **6**, 1656–1663.
- 13 E. Hoch, W. Lin, J. Chai, M. Hershfinkel, D. Fu and I. Sekler, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**, 7202–7207.
- 14 M. A. Lovell, J. L. Smith, S. Xiong and W. R. Markesbery, *Neurotox. Res.*, 2005, **7**, 265–271.
- 15 G. Lyubartseva, J. L. Smith, W. R. Markesbery and M. A. Lovell, *Brain Pathol.*, 2010, **20**, 343.
- 16 H. J. Bosomworth, P. A. Adlard, D. Ford and R. A. Valentine, *PLoS One*, 2013, **8**, e65475.
- 17 Y. Golan, T. Kambe and Y. G. Assaraf, *Metallomics*, 2017, **9**, 1352–1366.
- 18 M. C. Miletta, A. Bieri, K. Kernland, M. H. Schöni, V. Petkovic, C. E. Flück, A. Eblé and P. E. Mullis, *Int. J. Endocrinol.*, 2013, **2013**, 259189.
- 19 W. Chowanadisai, B. Lönnnerdal and S. L. Kelleher, *J. Biol. Chem.*, 2006, **281**, 39699–39707.
- 20 Y. Golan, A. Lehvy, G. Horev and Y. G. Assaraf, *J. Cell. Mol. Med.*, 2019, **23**, 828–840.
- 21 T. W. Boesgaard, J. Žilinskaitė, M. Vanttinen, M. Laakso, P.-A. Jansson, A. Hammarstedt, U. Smith, N. Stefan, A. Fritsche, H. Häring, M. Hribal, G. Sesti, D. P. Zobel, O. Pedersen, T. Hansen and the EUGENE 2 Consortium, *Diabetologia*, 2008, **51**, 816–820.
- 22 M. Quadri, A. Federico, T. Zhao, G. J. Breedveld, C. Battisti, C. Delnooz, L. A. Severijnen, L. Di Toro Mammarella, A. Mignarri, L. Monti, A. Sanna, P. Lu, F. Punzo, G. Cossu, R. Willemsen, F. Rasi, B. A. Oostra, B. P. Van De Warrenburg and V. Bonifati, *Am. J. Hum. Genet.*, 2012, **90**, 467–477.
- 23 K. Tuschl, P. T. Clayton, S. M. Gospe, S. Gulab, S. Ibrahim, P. Singhi, R. Aulakh, R. T. Ribeiro, O. G. Barsottini, M. S. Zaki, M. L. Del Rosario, S. Dyack, V. Price, A. Rideout, K. Gordon, R. A. Wevers, W. K. K. Chong and P. B. Mills, *Am. J. Hum. Genet.*, 2012, **90**, 457–466.
- 24 M. Mor, O. Beharier, S. Levy, J. Kahn, S. Dror, D. Blumenthal, L. A. Gheber, A. Peretz, A. Katz, A. Moran and Y. Etzion, *Am. J. Physiol. Physiol.*, 2012, **303**, C192–C203.
- 25 Y. Etzion, A. Ganiel, O. Beharier, A. Shalev, V. Novack, L. Volvich, D. Abrahamov, M. Matsa, G. Sahar, A. Moran and A. Katz, *J. Cardiovasc. Electrophysiol.*, 2008, **19**, 157–164.
- 26 S. Levy, O. Beharier, Y. Etzion, M. Mor, L. Buzaglo, L. Shaltiel, L. A. Gheber, J. Kahn, A. J. Muslin, A. Katz, D. Gitler and A. Moran, *J. Biol. Chem.*, 2009, **284**, 32434–32443.
- 27 O. Beharier, S. Dror, S. Levy, J. Kahn, M. Mor, S. Etzion, D. Gitler, A. Katz, A. J. Muslin, A. Moran and Y. Etzion, *J. Mol. Med.*, 2012, **90**, 127–138.
- 28 C. Merriman, Q. Huang, G. A. Rutter and D. Fu, *J. Biol. Chem.*, 2016, **291**, 26950–26957.
- 29 D. S. Parsons, C. Hogstrand and W. Maret, *FEBS J.*, 2018, **285**, 1237–1250.
- 30 R. Ullah, A. Shehzad, M. A. Shah, M. De March, F. Ismat, M. Iqbal, S. Onesti, M. Rahman and M. J. McPherson, *Int. J. Mol. Sci.*, 2020, **21**, 926.
- 31 N. Tanaka, M. Kawachi, T. Fujiwara and M. Masayoshi, *FEBS Open Bio.*, 2013, **3**, 218–224.
- 32 N. Tanaka, T. Fujiwara, R. Tomioka, U. Krämer, M. Kawachi and M. Maeshima, *Plant Cell Physiol.*, 2015, **56**, 510–519.
- 33 M. J. Daniels, M. Jagielnicki and M. Yeager, *Curr. Res. Struct. Biol.*, 2020, **2**, 144–155.
- 34 J. Xue, T. Xie, W. Zeng, Y. Jiang and X. Bai, *eLife*, 2020, **9**, e58823.
- 35 N. Coudray, S. Valvo, M. Hu, R. Lasala, C. Kim, M. Vink, M. Zhou, D. Provasi, M. Filizola, J. Tao, J. Fang, P. A. Penczek, I. Ubarretxena-Belandia and D. L. Stokes, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 2140–2145.
- 36 M. L. Lopez-Redondo, N. Coudray, Z. Zhang, J. Alexopoulos and D. L. Stokes, *Proc. Natl. Acad. Sci. U. S. A.*, 2018, **115**, 3042–3047.
- 37 M. Lu and D. Fu, *Science*, 2007, **317**, 1746–1748.
- 38 M. Lu, J. Chai and D. Fu, *Nat. Struct. Mol. Biol.*, 2009, **16**, 1063–1067.
- 39 O. Kolaj-Robin, D. Russell, K. A. Hayes, J. T. Pembroke and T. Soulimane, *FEBS Lett.*, 2015, **589**, 1283–1295.
- 40 N. Zeytuni, R. Uebe, M. Maes, G. Davidov, M. Baram, O. Raschdorf, M. Nadav-Tsubery, S. Kolusheva, R. Bitton, G. Goobes, A. Friedler, Y. Miller, D. Schüler and R. Zarivach, *PLoS One*, 2014, **9**, e92141.
- 41 V. Cherezov, N. Höfer, D. M. E. Szebenyi, O. Kolaj, J. G. Wall, R. Gillilan, V. Srinivasan, C. P. Jaroniec and M. Caffrey, *Structure*, 2008, **16**, 1378–1388.
- 42 N. Zeytuni, R. Uebe, M. Maes, G. Davidov, M. Baram, O. Raschdorf, A. Friedler, Y. Miller, D. Schüler and R. Zarivach, *PLoS One*, 2014, **9**, e97154.
- 43 R. Uebe, N. Keren-Khadmy, N. Zeytuni, E. Katzmann, Y. Navon, G. Davidov, R. Bitton, J. M. Plitzko, D. Schüler and R. Zarivach, *Mol. Microbiol.*, 2018, **107**, 542–557.



- 44 J. E. Martin and D. P. Giedroc, *J. Bacteriol.*, 2016, **198**, 1066–1076.
- 45 C. E. Zogzas, M. Aschner and S. Mukhopadhyay, *J. Biol. Chem.*, 2016, **291**, 15940–15957.
- 46 R. Uebe, K. Junge, V. Henn, G. Poxleitner, E. Katzmann, J. M. Plitzko, R. Zarivach, T. Kasama, G. Wanner, M. Pósfai, L. Böttger, B. Matzanke and D. Schüler, *Mol. Microbiol.*, 2011, **82**, 818–835.
- 47 A. Anton, A. Weltrowski, C. J. Haney, S. Franke, G. Grass, C. Rensing and D. H. Nies, *J. Bacteriol.*, 2004, **186**, 7499–7507.
- 48 R. D. Palmiter and S. D. Findley, *EMBO J.*, 1995, **14**, 639–649.
- 49 N. Itsumura, Y. Inamo, F. Okazaki, F. Teranishi, H. Narita, T. Kambe and H. Kodama, *PLoS One*, 2013, **8**, e64045.
- 50 Y. Chao and D. Fu, *J. Biol. Chem.*, 2004, **279**, 12043–12050.
- 51 S. Barber-Zucker, R. Uebe, G. Davidov, Y. Navon, D. Sherf, J. H. Chill, I. Kass, R. Bitton, D. Schüler and R. Zarivach, *Sci. Rep.*, 2016, **6**, 31933.
- 52 S. Barber-Zucker, J. Hall, S. V. Mangapuram, I. Kass, S. Kolusheva, F. MacMillan, R. Zarivach and A. Henn, *FEBS J.*, 2019, **286**, 2193–2215.
- 53 S. Barber-Zucker, J. Hall, A. Froes, S. Kolusheva, F. MacMillan and R. Zarivach, *J. Biol. Chem.*, 2020, **295**(49), 16614–16629.
- 54 T. Higuchi, M. Hattori, Y. Tanaka, R. Ishitani and O. Nureki, *Proteins: Struct., Funct., Bioinf.*, 2009, **76**, 768–771.
- 55 D. Poger, J. F. Fuchs, H. Nedev, M. Ferrand and S. Crouzy, *FEBS Lett.*, 2005, **579**, 5287–5292.
- 56 S. R. Udagedara, D. M. La Porta, C. Spehar, G. Purohit, M. J. A. Hein, M. E. Fatmous, G. P. Casas Garcia, K. Ganio, C. A. McDevitt and M. J. Maher, *J. Inorg. Biochem.*, 2020, **208**, 111087.
- 57 Y. Wei and D. Fu, *J. Biol. Chem.*, 2006, **281**, 23492–23502.
- 58 D. Sala, A. Giachetti and A. Rosato, *Biochim. Biophys. Acta, Gen. Subj.*, 2019, **1863**, 1560–1567.
- 59 S. Gupta, J. Chai, J. Cheng, R. D'Mello, M. R. Chance and D. Fu, *Nature*, 2014, **512**, 101–104.
- 60 S. Barber-Zucker, B. Shaanan and R. Zarivach, *Sci. Rep.*, 2017, **7**, 16381.
- 61 B. Montanini, D. Blaudez, S. Jeandroz, D. Sanders and M. Chalot, *BMC Genomics*, 2007, **8**, 107.
- 62 P. K. Menguer, E. Farthing, K. A. Peaston, F. K. Ricachenevsky, J. P. Fett and L. E. Williams, *J. Exp. Bot.*, 2013, **64**, 2871–2883.
- 63 Y. Nishito, N. Tsuji, H. Fujishiro, T. A. Takeda, T. Yamazaki, F. Teranishi, F. Okazaki, A. Matsunaga, K. Tuschl, R. Rao, S. Kono, H. Miyajima, H. Narita, S. Himeno and T. Kambe, *J. Biol. Chem.*, 2016, **291**, 14773–14787.
- 64 D. Podar, J. Scherer, Z. Noordally, P. Herzyk, D. Nies and D. Sanders, *J. Biol. Chem.*, 2012, **287**, 3185–3196.
- 65 M. Kawachi, Y. Kobae, T. Mimura and M. Maeshima, *J. Biol. Chem.*, 2008, **283**, 8374–8383.
- 66 M. Kawachi, Y. Kobae, S. Kogawa, T. Mimura, U. Krämer and M. Maeshima, *FEBS J.*, 2012, **279**, 2339–2356.
- 67 T. Suzuki, K. Ishihara, H. Migaki, K. Ishihara, M. Nagao, Y. Yamaguchi-Iwai and T. Kambe, *J. Biol. Chem.*, 2005, **280**, 30956–30962.
- 68 S. Barber-Zucker, A. Shahar, S. Kolusheva and R. Zarivach, *Sci. Rep.*, 2020, **10**, 14022.
- 69 G. Grass, M. Otto, B. Fricke, C. J. Haney, C. Rensing, D. H. Nies and D. Munkelt, *Arch. Microbiol.*, 2005, **183**, 9–18.
- 70 A. A. Guffanti, Y. Wei, S. V. Rood and T. A. Krulwich, *Mol. Microbiol.*, 2002, **45**, 145–153.
- 71 S. M. Lee, G. Grass, C. J. Haney, B. Fan, B. P. Rosen, A. Anton, D. H. Nies and C. Rensing, *FEMS Microbiol. Lett.*, 2002, **215**, 273–278.
- 72 D. Raimunda and G. Elso-Berberián, *Biochim. Biophys. Acta, Biomembr.*, 2014, **1838**, 3203–3211.
- 73 C. W. MacDiarmid, M. A. Milanick and D. J. Eide, *J. Biol. Chem.*, 2002, **277**, 39187–39194.
- 74 E. Ohana, E. Hoch, C. Keasar, T. Kambe, O. Yifrach, M. Hershfinkel and I. Sekler, *J. Biol. Chem.*, 2009, **284**, 17677–17686.
- 75 Y. Golan, R. Alhadeff, A. Warshel and Y. G. Assaraf, *PLoS Comput. Biol.*, 2019, **15**, e1006882.
- 76 K. Fukue, N. Itsumura, N. Tsuji, K. Nishino, M. Nagao, H. Narita and T. Kambe, *Sci. Rep.*, 2018, **8**, 14084.
- 77 C. Murgia, I. Vespignani, J. Cerase, F. Nobili and G. Perozzi, *Am. J. Physiol.: Gastrointest. Liver Physiol.*, 1999, **277**, G1231–1239.
- 78 I. Lasry, Y. A. Seo, H. Ityel, N. Shalva, B. Pode-Shakked, F. Glaser, B. Berman, I. Berezovsky, A. Goncarencu, A. Klar, J. Levy, Y. Anikster, S. L. Kelleher and Y. G. Assaraf, *J. Biol. Chem.*, 2012, **287**, 29348–29361.
- 79 Y. Golan, N. Itsumura, F. Glaser, B. Berman, T. Kambe and Y. G. Assaraf, *J. Biol. Chem.*, 2016, **291**, 13546–13559.
- 80 L. Marger, C. R. Schubert and D. Bertrand, *Biochem. Pharmacol.*, 2014, **91**, 426–435.
- 81 M. S. Hildebrand, A. M. Phillips, S. A. Mullen, P. A. Adlard, K. Hardies, J. A. Damiano, V. Wimmer, S. T. Bellows, J. M. McMahon, R. Burgess, R. Hendrickx, S. Weckhuysen, A. Suls, P. De Jonghe, I. E. Scheffer, S. Petrou, S. F. Berkovic and C. A. Reid, *Sci. Rep.*, 2016, **5**, 17816.
- 82 G. Salazar, J. M. Falcon-Perez, R. Harrison and V. Faundez, *PLoS One*, 2009, **4**, e5896.
- 83 F. Chimienti, S. Devergnas, A. Favier and M. Seve, *Diabetes*, 2004, **53**, 2330–2337.
- 84 J. Flannick, G. Thorleifsson, N. L. Beer, S. B. R. Jacobs, N. Grarup, N. P. Burtt, A. Mahajan, C. Fuchsberger, G. Atzmon, R. Benediktsson, J. Blangero, D. W. Bowden, I. Brandslund, J. Brosnan, F. Burslem, J. Chambers, Y. S. Cho, C. Christensen, D. A. Douglas, R. Duggirala, Z. Dymek, Y. Farjoun, T. Fennell, P. Fontanillas, T. Forsén, S. Gabriel, B. Glaser, D. F. Gudbjartsson, C. Hanis, T. Hansen, A. B. Hreidarsson, K. Hveem, E. Ingelsson, B. Isomaa, S. Johansson, T. Jørgensen, M. E. Jørgensen, S. Kathiresan, A. Kong, J. Kooner, J. Kravic, M. Laakso, J.-Y. Lee, L. Lind, C. M. Lindgren, A. Linneberg, G. Masson,



- T. Meitinger, K. L. Mohlke, A. Molven, A. P. Morris, S. Potluri, R. Rauramaa, R. Ribel-Madsen, A.-M. Richard, T. Rolph, V. Salomaa, A. V. Segrè, H. Skärstrand, V. Steinhorsdottir, H. M. Stringham, P. Sulem, E. S. Tai, Y. Y. Teo, T. Teslovich, U. Thorsteinsdottir, J. K. Trimmer, T. Tuomi, J. Tuomilehto, F. Vaziri-Sani, B. F. Voight, J. G. Wilson, M. Boehnke, M. I. McCarthy, P. R. Njølstad, O. Pedersen, L. Groop, D. R. Cox, K. Stefansson, D. Altshuler, K. Stefansson and D. Altshuler, *Nat. Genet.*, 2014, **46**, 357–363.
- 85 M. Tyszka-Czochara, A. Grzywacz, J. Gdula-Argasi-Ska, T. Librowski, B. Wili-Ski and W. Opoka, *Acta Pol. Pharm.*, 2014, **71**, 369–377.
- 86 M. Seve, F. Chimienti, S. Devergnas and A. Favier, *BMC Genomics*, 2004, **5**, 32.
- 87 D. Leyva-Illades, P. Chen, C. E. Zogzas, S. Hutchens, J. M. Mercado, C. D. Swaim, R. A. Morrisett, A. B. Bowman, M. Aschner and S. Mukhopadhyay, *J. Neurosci.*, 2014, **34**, 14079–14095.
- 88 R. J. Cousins, J. P. Liuzzi and L. A. Lichten, *J. Biol. Chem.*, 2006, **281**, 24085–24089.
- 89 C. Nolte, A. Gore, I. Sekler, W. Kresse, M. Hershinkel, A. Hoffmann, H. Kettenmann and A. Moran, *Glia*, 2004, **48**, 145–155.
- 90 T. Kambe, T. Tsuji, A. Hashimoto and N. Isumura, *Physiol. Rev.*, 2015, **95**, 749–784.
- 91 T. Kimura and T. Kambe, *Int. J. Mol. Sci.*, 2016, **17**, 336.
- 92 M. Tsuda, K. Imaizumi, T. Katayama, K. Kitagawa, A. Wanaka, M. Tohyama and T. Takagi, *J. Neurosci.*, 1997, **17**, 6678–6684.
- 93 S. J. Langmade, R. Ravindra, P. J. Daniels and G. K. Andrews, *J. Biol. Chem.*, 2000, **275**, 34803–34809.
- 94 M. Vig, C. Peinelt, A. Beck, D. L. Koomoa, D. Rabah, M. Koblan-Huberson, S. Kraft, H. Turner, A. Fleig, R. Penner and J. P. Kinet, *Science*, 2006, **312**, 1220–1223.
- 95 T. K. Adams, N. Saydam, F. Steiner, W. Schaffner and J. H. Freedman, *Environ. Health Perspect.*, 2002, **110**, 813–817.
- 96 T. P. Dalton, Q. Li, D. Bittel, L. Liang and G. K. Andrews, *J. Biol. Chem.*, 1996, **271**, 26233–26241.
- 97 O. Beharier, Y. Etzion, A. Katz, H. Friedman, N. Tenbosh, S. Zacharish, S. Bereza, U. Goshen and A. Moran, *Cell Calcium*, 2007, **42**, 71–82.
- 98 E. Shusterman, O. Beharier, S. Levy, R. Zarivach, Y. Etzion, C. R. Campbell, I. H. Lee, A. Dinudom, D. I. Cook, A. Peretz, A. Katz, D. Gitler and A. Moran, *Metallomics*, 2017, **9**, 228–238.
- 99 G. K. Andrews, H. Wang, S. K. Dey and R. D. Palmiter, *Genesis*, 2004, **40**, 74–81.
- 100 J. J. Bruinsma, T. Jirakulaporn, A. J. Muslin and K. Kornfeld, *Dev. Cell*, 2002, **2**, 567–578.
- 101 T. Jirakulaporn and A. J. Muslin, *J. Biol. Chem.*, 2004, **279**, 27807–27815.
- 102 D. Segal, E. Ohana, L. Besser, M. Hershinkel, A. Moran and I. Sekler, *Biochem. Biophys. Res. Commun.*, 2004, **323**, 1145–1150.
- 103 F. A. O'Rourke, J. M. LaPlante and M. B. Feinstein, *Biochem. J.*, 2003, **373**, 133–143.
- 104 M. Y. Song, A. Makino and J. X.-J. Yuan, *Antioxid. Redox Signaling*, 2011, **15**, 1549–1565.
- 105 M. Lazarczyk, P. Cassonnet, C. Pons, Y. Jacob and M. Favre, *Microbiol. Mol. Biol. Rev.*, 2009, **73**, 348–370.
- 106 E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng and T. E. Ferrin, *J. Comput. Chem.*, 2004, **25**, 1605–1612.

